{"name":"Syneos Health","slug":"syneos-health","ticker":"","exchange":"","domain":"","description":"Syneos Health is an American company that provides contract research and commercial services to pharmaceutical and biotechnology companies. Based in Morrisville, North Carolina, the company specializes in helping other companies with late-stage clinical trials, but also provides commercial services to market health treatments.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5393082000,"revenueGrowth":3.5,"grossMargin":0,"rdSpend":0,"netIncome":266497000,"cash":8199218000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Orally Suspension of CoV2-OGEN1","genericName":"Orally Suspension of CoV2-OGEN1","slug":"orally-suspension-of-cov2-ogen1","indication":"Other","status":"phase_1"},{"name":"Tocilizumab Prefilled Syringe","genericName":"Tocilizumab Prefilled Syringe","slug":"tocilizumab-prefilled-syringe","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Orally Suspension of CoV2-OGEN1","genericName":"Orally Suspension of CoV2-OGEN1","slug":"orally-suspension-of-cov2-ogen1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tocilizumab Prefilled Syringe","genericName":"Tocilizumab Prefilled Syringe","slug":"tocilizumab-prefilled-syringe","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1udGJqbDVXVE9TMzlFTkdUOTdXQUlCZUhCVmdWV1N1SEZHb2pydHVJN0Jub3AtRHE3NGZPSzlsdEJCOFhkaVBLRlRFRGRzbl9MRnBIWnRvZTlERTVHemo4Qmk4dEpGdTloREtIMnpXajRJU21qMG1PakhqdUVDdw?oc=5","date":"2026-02-20","type":"pipeline","source":"Statista","summary":"Synoes Health employee number 2014-2022 - Statista","headline":"Synoes Health employee number 2014-2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5DamdLVDRsS3J5b2N5WUpiX1VFUGswcWRFalRIYmVFYmdscFcwbF9WdzU2YlNUTS1aVWtLUGZXVVNEWUxIdzQtc3p6QWFnb3BYbXJfbDVEV0pIZXhjSEN6VlpB?oc=5","date":"2026-02-12","type":"pipeline","source":"Fierce Pharma","summary":"Beyond Forecasts: Navigating MFN Uncertainty - Fierce Pharma","headline":"Beyond Forecasts: Navigating MFN Uncertainty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxONzJqS0RGNXlSY2JtMEo2QnV1SmVIbDc2Qzl3MERIZHVacnNicDZTd3BJNWE0ZF96a3pQLTBtb3ZsS09PM3ZMdldFMmRpOTVCdkJmYXFSSi12UlJZaFVJYUFzV25yWWd0SlVWbUJqUUZJSmJweUZFOG9EZE5UOGtNZS1aemhkTEdaR1VPaS03V19SWW5DVGVDTEwxTE5FaTA2c3hUN1FnSVRTeFpReWZNWWZxUGpXcldXdS1WR3l6Q21qUzVi?oc=5","date":"2026-01-13","type":"pipeline","source":"Syneos Health","summary":"The Trust Era: How Experience and Prediction Are Redefining Pharma’s Relationship With Patients - Syneos Health","headline":"The Trust Era: How Experience and Prediction Are Redefining Pharma’s Relationship With Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMU5nVWFDdVZqV0VoMVh1dmNKNkNwcGt0QXZnYzJnOGZTazZPLWhJdEFyT0lhalB4N3V1X1N5OHpiWmdscEVhM2NHVDM1aHBFMTNQUnllekQxWHRlLXBMT25FOUhxS291WmluNGVVelhRRUtXRnZkRlB2QUJCa3RNY0laeUZvdjlvVTVwRldEal9WYjRkbC1RcmlGQzdWUWZfaXBGTzhTNV9mSEE?oc=5","date":"2025-10-28","type":"pipeline","source":"Medical Marketing and Media","summary":"Answer Engine Optimization: Why it matters for pharma and biotech - Medical Marketing and Media","headline":"Answer Engine Optimization: Why it matters for pharma and biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQUktHeFZRUl9CbmI5MFBNX2FxUlFJbU5jMk9VczhQbVJWdjJEV2JuT1dWSGd4Y3hUekhyNEJ5bGlDbGRCSEM2NkttSndxMTZoMnFXbnp1WFFVTExLSkdPMXVXdjhBSGpjM19Nd1V3aVpZS0NQRkRtTHdTNjREM0dRU3VWbDNMbjg0VHV6aHEzSkNmTDhNRVIwRFFGNHoybTNjQXVXeTVzYWdDeUhzaGdCaDIwc0w?oc=5","date":"2025-10-13","type":"pipeline","source":"Fierce Pharma","summary":"Syneos Health’s Lehmann: Commercial strategies must evolve with specialty medicine - Fierce Pharma","headline":"Syneos Health’s Lehmann: Commercial strategies must evolve with specialty medicine","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-25","type":"trial","source":"Medical Dialogues","summary":"Syneos Health Asked to Clarify Phase II Tacrolimus Trial Protocol by CDSCO Panel - Medical Dialogues","headline":"Syneos Health Asked to Clarify Phase II Tacrolimus Trial Protocol by CDSCO Panel","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-24","type":"trial","source":"Medical Dialogues","summary":"CDSCO Panel Rejects Phase III Trial of QL2107 Injection Proposed by Syneos Health - Medical Dialogues","headline":"CDSCO Panel Rejects Phase III Trial of QL2107 Injection Proposed by Syneos Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPRkw5Z3VhbFpXU3FhZW5NNVN6cEFrZ21SZTFmenNxNldMdWZYam1qcTU3SUlELVNoT3JjNzBmSHg1Q3pmdUNPVVYxMVpzRFVESThrUUwxaV9tNWNReGZlSFVCVEtTdTR5ZjE2dHdPRkE5U3EwY29VNXV5dUlQNWRnc0VvSktDNlNWSDJSSDZURkRTZ1JQclBLRURQQWxjMUY4cWdFRmZldlp2TTJJLTJaejNLM2g0OXZuLUw5aVlR?oc=5","date":"2025-08-04","type":"deal","source":"Syneos Health","summary":"Pharma System Implementations: Ensuring Adoption Through Process and Change Team Collaboration - Syneos Health","headline":"Pharma System Implementations: Ensuring Adoption Through Process and Change Team Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPUk1CbEZGd080TWdlWnBGOTJHZG04d2swYVF0ZXlzQ0REQ0JMbjZJbkpNUkFaMW9sWXdIZTJQbVJpaV83eC1EYUd2czJNQ0JNREZVbjhXdzVCZmNESFotOVNkVVlzamowWUk4QmJtZEp3c0MzU282aHByQy1aUHpLMk5vdXJ3S3VlbU5KRDJEV200MHdZY1FqXw?oc=5","date":"2025-07-28","type":"pipeline","source":"Syneos Health","summary":"Investing for Launch Success: What Matters Most (and When) - Syneos Health","headline":"Investing for Launch Success: What Matters Most (and When)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOekkzNGg3SzRCMVYtUXB3QWh3aGROejBMWFcxeWVyQmJqSzZPRGlYUjFSYmJwa1BBUzI3WHYxSXJsMXc2TnJpOElfbWdGWTBjWUtKT2ptbGdVSTJWeWJIN0tQTTViQ1dxYUNxcWREeXZBRllJLUwtX3RYczVCNHJNZnRZOVY4NzNiLTFUUk50eElsNVRKVnMtX0RFUEt1ejhDZ0xCN3pBbHdWX1JGQm5kdjZR?oc=5","date":"2025-07-21","type":"pipeline","source":"Syneos Health","summary":"Why Early Patient Advocacy Matters: What Pharma Can Learn from Brand Loyalty - Syneos Health","headline":"Why Early Patient Advocacy Matters: What Pharma Can Learn from Brand Loyalty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPZWI4ODgyWnRjZkYxZjc5RU9yTnAwM1JMZ21TSFl0Umh1VTVqY3pWci1NNlJqWVpGbm1hYVM2a3ZoSURKM3AxRGwyazBWVTFJaWhQRnh1UjZ4TDZ1NEVJUDQ1NmR2R2NDQzZRam51QzVsSlMwNVUzcWE0MVlJZjdmUml4RGl5LS10dmhHM2xwSkRHZ1ctMXFXUVVJd1d0TERKZkFiNWF3aXU3Wl9MWW5lVng4WVpJMXFNLTNlREJNcw?oc=5","date":"2025-06-26","type":"pipeline","source":"PharmaLive","summary":"Syneos Health Communications launches Empathy Engine to revolutionize healthcare communication - PharmaLive","headline":"Syneos Health Communications launches Empathy Engine to revolutionize healthcare communication","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPMnRycTRRaHBKSjAwaEViczhFYkszSVNnQXlSb29kU0tsbkhKcnpGSWdrNjF3cGhWblM3V1A5Zkd0YzdFV0NzSjBENVNpVjg4a3I3OXdxbzhSUWlFZlduY09XbTR1YmFiSjEwYnZtV1ZvazNWYVJJNnFONEViY2wwYkduS0RRT2ZlZEstQnV1MA?oc=5","date":"2025-03-18","type":"trial","source":"Microsoft","summary":"Syneos Health reduces time for clinical trial site activation by about 10% with Azure OpenAI Service - Microsoft","headline":"Syneos Health reduces time for clinical trial site activation by about 10% with Azure OpenAI Service","sentiment":"neutral"},{"date":"2023-10-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5393082000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":5393082000,"period":"2022-12-31"},{"value":5212970000,"period":"2021-12-31"},{"value":5212970000,"period":"2021-12-31"},{"value":4415777000,"period":"2020-12-31"},{"value":4415777000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":266497000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":8199218000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}